标题
Targeting KRAS in pancreatic cancer: new drugs on the horizon
作者
关键词
-
出版物
CANCER AND METASTASIS REVIEWS
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-09-09
DOI
10.1007/s10555-021-09990-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- KRAS drives immune evasion in a genetic model of pancreatic cancer
- (2021) Irene Ischenko et al. Nature Communications
- Searching for treatments for non-G12C-KRAS mutant cancers
- (2021) Christina Guo et al. BRITISH JOURNAL OF CANCER
- Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells
- (2021) Tatsunori Suzuki et al. CANCER GENE THERAPY
- The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
- (2021) David M. Briere et al. MOLECULAR CANCER THERAPEUTICS
- Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation
- (2021) Noritaka Tanaka et al. Cancer Discovery
- Bone marrow-derived macrophages converted into cancer-associated fibroblast-like cells promote pancreatic cancer progression
- (2021) Chika Iwamoto et al. CANCER LETTERS
- Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment
- (2021) D. Lucas Kerr et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Acquired Resistance to KRASG12C Inhibition in Cancer
- (2021) Mark M. Awad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interactions between Cancer-Associated Fibroblasts and T Cells in the Pancreatic Tumor Microenvironment and the Role of Chemokines
- (2021) Laia Gorchs et al. Cancers
- KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
- (2020) Misako Nagasaka et al. CANCER TREATMENT REVIEWS
- Oncogenic Kras driven metabolic reprogramming in pancreas cancer cells utilizes cytokines from the tumor microenvironment
- (2020) Prasenjit Dey et al. Cancer Discovery
- Computational Prediction and Validation of Tumor-Associated Neoantigens
- (2020) Vladimir Roudko et al. Frontiers in Immunology
- Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research
- (2020) Zhidong Wang et al. Frontiers in Immunology
- Targeting the MAPK Pathway in KRAS-Driven Tumors
- (2020) Matthias Drosten et al. CANCER CELL
- Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
- (2020) Jay B. Fell et al. JOURNAL OF MEDICINAL CHEMISTRY
- Tumor microenvironment remodeling enables bypass of oncogenic KRAS dependency in pancreatic cancer
- (2020) Pingping Hou et al. Cancer Discovery
- Immunotherapy for pancreatic cancer: A 2020 update
- (2020) Dimitrios Schizas et al. CANCER TREATMENT REVIEWS
- Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer
- (2020) Junfei Cheng et al. JOURNAL OF MEDICINAL CHEMISTRY
- RAS-targeted therapies: is the undruggable drugged?
- (2020) Amanda R. Moore et al. NATURE REVIEWS DRUG DISCOVERY
- The type of KRAS mutation drives PI3Kα/γ signalling dependency: Implication for the choice of targeted therapy in pancreatic adenocarcinoma patients
- (2020) Coralie Cayron et al. Clinics and Research in Hepatology and Gastroenterology
- Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs
- (2020) Michael J. Bond et al. ACS Central Science
- Post-translational modification of KRAS: potential targets for cancer therapy
- (2020) Wei-hua Wang et al. ACTA PHARMACOLOGICA SINICA
- Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling
- (2020) Huai-Xiang Hao et al. CLINICAL CANCER RESEARCH
- mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer
- (2020) Gal Cafri et al. JOURNAL OF CLINICAL INVESTIGATION
- SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
- (2020) Carmine Fedele et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer
- (2020) Matthew J. LaMarche et al. JOURNAL OF MEDICINAL CHEMISTRY
- BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition
- (2020) Marco H Hofmann et al. Cancer Discovery
- GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf
- (2020) Ziyang Zhang et al. ACS Central Science
- Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo
- (2020) Kotaro Sakamoto et al. Scientific Reports
- SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors
- (2019) Tamer A. Ahmed et al. Cell Reports
- Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction
- (2019) Roman C. Hillig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer
- (2019) Christopher J. Halbrook et al. Cell Metabolism
- Understanding Cell Penetration of Cyclic Peptides
- (2019) Patrick G. Dougherty et al. CHEMICAL REVIEWS
- The effects and the mechanisms of autophagy on the cancer-associated fibroblasts in cancer
- (2019) Yuanliang Yan et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Sequential Targeting TGF‐β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer
- (2019) Yuanyuan Pei et al. Small
- Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer
- (2019) Thomas B. Karasic et al. JAMA Oncology
- Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors
- (2019) Aslamuzzaman Kazi et al. CLINICAL CANCER RESEARCH
- Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance
- (2019) Simona Dalin et al. CANCER RESEARCH
- Development of targeted protein degradation therapeutics
- (2019) Philip P. Chamberlain et al. Nature Chemical Biology
- KRAS-Driven Metabolic Rewiring Reveals Novel Actionable Targets in Cancer
- (2019) Emanuela Pupo et al. Frontiers in Oncology
- Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition
- (2019) Meagan B. Ryan et al. CLINICAL CANCER RESEARCH
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
- (2019) G. Aaron Hobbs et al. Cancer Discovery
- The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- (2019) Jill Hallin et al. Cancer Discovery
- Genetic landscape of prognostic value in pancreatic ductal adenocarcinoma microenvironment
- (2019) Ning Pu et al. Annals of Translational Medicine
- Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
- (2018) Matthew R. Janes et al. CELL
- Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
- (2018) Dietrich A. Ruess et al. NATURE MEDICINE
- Ras-Mediated Activation of the Raf Family Kinases
- (2018) Elizabeth M. Terrell et al. Cold Spring Harbor Perspectives in Medicine
- Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma
- (2018) Zhi Rong Qian et al. JAMA Oncology
- RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
- (2018) Robert J. Nichols et al. NATURE CELL BIOLOGY
- SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models
- (2018) Carmine Fedele et al. Cancer Discovery
- Cancer Neoantigens
- (2018) Ton N. Schumacher et al. Annual Review of Immunology
- Targeting the α4–α5 dimerization interface of K-RAS inhibits tumor formation in vivo
- (2018) Imran Khan et al. ONCOGENE
- Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes
- (2018) Andrew McGuigan et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
- (2017) Ugur Sahin et al. NATURE
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- Inhibition of mTORC2 component RICTOR impairs tumor growth in pancreatic cancer models
- (2017) Katharina M. Schmidt et al. Oncotarget
- Nucleotide based covalent inhibitors of KRas can only be efficient in vivo if they bind reversibly with GTP-like affinity
- (2017) Matthias P. Müller et al. Scientific Reports
- mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer
- (2016) David R. Driscoll et al. CANCER RESEARCH
- Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation
- (2016) Christopher J. Tape et al. CELL
- The Significance of Ras Activity in Pancreatic Cancer Initiation
- (2016) Craig D. Logsdon et al. International Journal of Biological Sciences
- Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions
- (2016) Paul A. Jackson et al. JOURNAL OF MEDICINAL CHEMISTRY
- How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization
- (2016) Ethan J. Brock et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion
- (2016) Cristovão M. Sousa et al. NATURE
- Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
- (2016) Ying-Nan P. Chen et al. NATURE
- Genomic analyses identify molecular subtypes of pancreatic cancer
- (2016) Peter Bailey et al. NATURE
- Inhibition of RAS function through targeting an allosteric regulatory site
- (2016) Russell Spencer-Smith et al. Nature Chemical Biology
- Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
- (2016) Jonathan M. L. Ostrem et al. NATURE REVIEWS DRUG DISCOVERY
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sos1 disruption impairs cellular proliferation and viability through an increase in mitochondrial oxidative stress in primary MEFs
- (2016) P Liceras-Boillos et al. ONCOGENE
- KRAS-related proteins in pancreatic cancer
- (2016) Karen M. Mann et al. PHARMACOLOGY & THERAPEUTICS
- Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
- (2016) P. Lito et al. SCIENCE
- Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
- (2016) M. P. Patricelli et al. Cancer Discovery
- Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism
- (2016) Hongyun Zhao et al. eLife
- KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma
- (2016) Barbara Bournet et al. Clinical and Translational Gastroenterology
- Ras activation revisited: role of GEF and GAP systems
- (2015) Anne Hennig et al. BIOLOGICAL CHEMISTRY
- Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
- (2015) Sheng-Bin Peng et al. CANCER CELL
- Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
- (2015) J. C. Hunter et al. MOLECULAR CANCER RESEARCH
- Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2
- (2015) H. P. Soares et al. MOLECULAR CANCER THERAPEUTICS
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- Allelic Ratio of KRAS Mutations in Pancreatic Cancer
- (2015) J. K. Lennerz et al. ONCOLOGIST
- A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
- (2015) B. M. Carreno et al. SCIENCE
- Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
- (2015) Agnieszka K. Witkiewicz et al. Nature Communications
- Pancreatic Adenocarcinoma
- (2015) David P. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ral small GTPase signaling and oncogenesis: More than just 15minutes of fame
- (2014) Leanna R. Gentry et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
- (2014) Andrew D. Rhim et al. CANCER CELL
- Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy
- (2014) Mara H. Sherman et al. CELL
- Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma
- (2014) B. M. Wolpin et al. ONCOLOGIST
- The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells
- (2014) Makoto Wada et al. PLoS One
- Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange
- (2014) Michael C. Burns et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Recombinant expression of different mutant K-ras gene in pancreatic cancer Bxpc-3 cells and its effects on chemotherapy sensitivity
- (2014) TengFei Shao et al. Science China-Life Sciences
- BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling
- (2014) B. Sanchez-Laorden et al. Science Signaling
- KRAS: feeding pancreatic cancer proliferation
- (2014) Kirsten L. Bryant et al. TRENDS IN BIOCHEMICAL SCIENCES
- Dosage-Dependent Regulation of Pancreatic Cancer Growth and Angiogenesis by Hedgehog Signaling
- (2014) Esha Mathew et al. Cell Reports
- Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity
- (2013) Nobuya Ishii et al. CANCER RESEARCH
- Targeting the RAS oncogene
- (2013) Asami Takashima et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Metabolic Alterations in Lung Cancer–Associated Fibroblasts Correlated with Increased Glycolytic Metabolism of the Tumor
- (2013) Virendra K. Chaudhri et al. MOLECULAR CANCER RESEARCH
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Oncogenic K-Ras requires activation for enhanced activity
- (2013) H Huang et al. ONCOGENE
- Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment
- (2013) X Sui et al. Cell Death & Disease
- EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma
- (2012) Carolina Navas et al. CANCER CELL
- EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis
- (2012) Christine M. Ardito et al. CANCER CELL
- A Comprehensive Survey of Ras Mutations in Cancer
- (2012) I. A. Prior et al. CANCER RESEARCH
- Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
- (2012) Haoqiang Ying et al. CELL
- Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers
- (2012) S. Dogan et al. CLINICAL CANCER RESEARCH
- Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia
- (2012) Mitsuro Kanda et al. GASTROENTEROLOGY
- An NF-κB pathway–mediated positive feedback loop amplifies Ras activity to pathological levels in mice
- (2012) Jaroslaw Daniluk et al. JOURNAL OF CLINICAL INVESTIGATION
- Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
- (2012) Meredith A. Collins et al. JOURNAL OF CLINICAL INVESTIGATION
- Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer
- (2012) Takeshi Ogura et al. JOURNAL OF GASTROENTEROLOGY
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
- (2012) Nathan T. Ihle et al. JNCI-Journal of the National Cancer Institute
- Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer
- (2012) T. M. Williams et al. MOLECULAR CANCER THERAPEUTICS
- Metastatic Pancreatic Cancer Is Dependent on Oncogenic Kras in Mice
- (2012) Meredith A. Collins et al. PLoS One
- Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression
- (2011) Paolo Cirri et al. CANCER AND METASTASIS REVIEWS
- Pancreatic cancers require autophagy for tumor growth
- (2011) S. Yang et al. GENES & DEVELOPMENT
- The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins
- (2011) Anchal Chandra et al. NATURE CELL BIOLOGY
- Regulating the regulator: post-translational modification of RAS
- (2011) Ian M. Ahearn et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
- (2010) Milind M Javle et al. BMC CANCER
- PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling
- (2010) E. Halilovic et al. CANCER RESEARCH
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- Overexpression of Smoothened Activates the Sonic Hedgehog Signaling Pathway in Pancreatic Cancer-Associated Fibroblasts
- (2010) K. Walter et al. CLINICAL CANCER RESEARCH
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway
- (2009) Edoardo Missiaglia et al. JOURNAL OF CLINICAL ONCOLOGY
- Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis
- (2009) H. Tian et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
- (2008) Brian M. Wolpin et al. JOURNAL OF CLINICAL ONCOLOGY
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
- The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway
- (2007) Marie Dance et al. CELLULAR SIGNALLING
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More